Lumito’s technology addresses challenges in several application areas, which can be divided into three main groups:
In these areas, existing methods for tissue analysis have gaps in relation to sensitivity and precise quantification, gaps that are bridged with the Lumito SCIZYS system. The SCIZYS system thus allows for a higher degree of objectivity in judgments and decision-making.
* Lumito’s platform is not approved for clinical use and assessment of patient results for diagnostic purposes is not an approved application.
UCNPs provide a unique optical advantage, when excited with near‑infrared (NIR) light, they emit higher‑energy photons. This property results in autofluorescence‑free imaging, enabling the detection of weak biomarker signals that typically disappear in background noise when using other methods.
Key technological benefits highlighted in the white paper include:
These properties create a robust platform for biomarker quantification, even in challenging low‑expression contexts.
For more information download our white paper:
The Lumito SCIZYS system is an open platform for immunohistochemistry (IHC). The SCIZYS UCNPs can be attached to any biotinylated molecule and the system is agnostic to tissue type, enabling a wide range of uses. We are co-developing application areas together with our customers and partners. Areas with significant interest and potential include: